FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1844254983> ?p ?o ?g. }

• W1844254983 endingPage "73" @default.
• W1844254983 startingPage "69" @default.
• W1844254983 abstract "Polycystic ovarian syndrome (PCOS) induces anovulation in women of reproductive age, and is one of the pathological factors involved in the failure of in vitro fertilization (IVF). Indeed, PCOS women are characterized by poor quality oocytes. Therefore, a treatment for enhancing oocyte quality becomes crucial for these patients. Myo-Inositol and melatonin proved to be efficient predictors for positive IVF outcomes, correlating with high oocyte quality. We tested the synergistic effect of myo-inositol and melatonin in IVF protocols with PCOS patients in a randomized, controlled, double-blind trial. Five-hundred twenty-six PCOS women were divided into three groups: Controls (only folic acid: 400 mcg), Group A (Inofolic® plus, a daily dose of myo-inositol: 4000 mg, folic acid: 400 mcg, and melatonin: 3 mg), and Group B (Inofolic®, a daily dose of myo-inositol: 4000 mg, and folic acid: 400 mcg). The main outcome measures were oocyte and embryo quality, clinical pregnancy and implantation rates. The treatment lasted from the first day of the cycle until 14 days after embryo transfer. Myo-inositol and melatonin have shown to enhance, synergistically, oocyte and embryo quality. In consideration of the beneficial effect observed in our trial and on the bases of previous studies, we decided to integrate routinely MI and M supplementation in the IVF protocols. The same treatment should be taken carefully in consideration in all procedures of this kind." @default.
• W1844254983 created "2016-06-24" @default.
• W1844254983 creator A5047870998 @default.
• W1844254983 creator A5059290297 @default.
• W1844254983 creator A5061927482 @default.
• W1844254983 creator A5065247912 @default.
• W1844254983 date "2015-10-28" @default.
• W1844254983 modified "2023-10-18" @default.
• W1844254983 title "Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving<i>in vitro</i>fertilization of patients with polycystic ovarian syndrome" @default.
• W1844254983 cites W1485887944 @default.
• W1844254983 cites W1534163224 @default.
• W1844254983 cites W1985148854 @default.
• W1844254983 cites W1987486444 @default.
• W1844254983 cites W1989095867 @default.
• W1844254983 cites W2005318658 @default.
• W1844254983 cites W2011606314 @default.
• W1844254983 cites W2025044870 @default.
• W1844254983 cites W2026082686 @default.
• W1844254983 cites W2034348289 @default.
• W1844254983 cites W2044406786 @default.
• W1844254983 cites W2056107937 @default.
• W1844254983 cites W2058619337 @default.
• W1844254983 cites W2064886376 @default.
• W1844254983 cites W2065372082 @default.
• W1844254983 cites W2070269316 @default.
• W1844254983 cites W2072290318 @default.
• W1844254983 cites W2076550840 @default.
• W1844254983 cites W2086703069 @default.
• W1844254983 cites W2090555668 @default.
• W1844254983 cites W2095827504 @default.
• W1844254983 cites W2104960054 @default.
• W1844254983 cites W2118531093 @default.
• W1844254983 cites W2118600958 @default.
• W1844254983 cites W2131391777 @default.
• W1844254983 cites W2134700543 @default.
• W1844254983 cites W2134896102 @default.
• W1844254983 cites W2141617338 @default.
• W1844254983 cites W2142115443 @default.
• W1844254983 cites W2144157059 @default.
• W1844254983 cites W2145984551 @default.
• W1844254983 cites W2147545348 @default.
• W1844254983 cites W2156191286 @default.
• W1844254983 cites W2158919338 @default.
• W1844254983 cites W2160945331 @default.
• W1844254983 cites W2165846997 @default.
• W1844254983 cites W2036017108 @default.
• W1844254983 doi "https://doi.org/10.3109/09513590.2015.1101444" @default.
• W1844254983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26507336" @default.
• W1844254983 hasPublicationYear "2015" @default.
• W1844254983 type Work @default.
• W1844254983 sameAs 1844254983 @default.
• W1844254983 citedByCount "66" @default.
• W1844254983 countsByYear W18442549832013 @default.
• W1844254983 countsByYear W18442549832016 @default.
• W1844254983 countsByYear W18442549832017 @default.
• W1844254983 countsByYear W18442549832018 @default.
• W1844254983 countsByYear W18442549832019 @default.
• W1844254983 countsByYear W18442549832020 @default.
• W1844254983 countsByYear W18442549832021 @default.
• W1844254983 countsByYear W18442549832022 @default.
• W1844254983 countsByYear W18442549832023 @default.
• W1844254983 crossrefType "journal-article" @default.
• W1844254983 hasAuthorship W1844254983A5047870998 @default.
• W1844254983 hasAuthorship W1844254983A5059290297 @default.
• W1844254983 hasAuthorship W1844254983A5061927482 @default.
• W1844254983 hasAuthorship W1844254983A5065247912 @default.
• W1844254983 hasConcept C126322002 @default.
• W1844254983 hasConcept C134018914 @default.
• W1844254983 hasConcept C160099875 @default.
• W1844254983 hasConcept C16685009 @default.
• W1844254983 hasConcept C168563851 @default.
• W1844254983 hasConcept C196843134 @default.
• W1844254983 hasConcept C2776537878 @default.
• W1844254983 hasConcept C2776690073 @default.
• W1844254983 hasConcept C2777391703 @default.
• W1844254983 hasConcept C2777542035 @default.
• W1844254983 hasConcept C2777688143 @default.
• W1844254983 hasConcept C2778182776 @default.
• W1844254983 hasConcept C2779234561 @default.
• W1844254983 hasConcept C2780853582 @default.
• W1844254983 hasConcept C29456083 @default.
• W1844254983 hasConcept C3018442814 @default.
• W1844254983 hasConcept C511355011 @default.
• W1844254983 hasConcept C512716672 @default.
• W1844254983 hasConcept C54355233 @default.
• W1844254983 hasConcept C71924100 @default.
• W1844254983 hasConcept C86803240 @default.
• W1844254983 hasConcept C95444343 @default.
• W1844254983 hasConceptScore W1844254983C126322002 @default.
• W1844254983 hasConceptScore W1844254983C134018914 @default.
• W1844254983 hasConceptScore W1844254983C160099875 @default.
• W1844254983 hasConceptScore W1844254983C16685009 @default.
• W1844254983 hasConceptScore W1844254983C168563851 @default.
• W1844254983 hasConceptScore W1844254983C196843134 @default.
• W1844254983 hasConceptScore W1844254983C2776537878 @default.
• W1844254983 hasConceptScore W1844254983C2776690073 @default.
• W1844254983 hasConceptScore W1844254983C2777391703 @default.
• W1844254983 hasConceptScore W1844254983C2777542035 @default.

• next